all report title image
  • Published On : Apr 2021
  • Code : CMI4166
  • Industry : Pharmaceutical
  • Pages : 164
  • Formats :

Toxoplasmosis is a zoonotic infection, which is caused by the parasite toxoplasma gondii with a wide range of clinical syndromes in humans. Toxoplasmosis is a potentially life-threatening, serious, and sometimes fatal infection. The Centers for Disease Control and Prevention (CDC) has considered toxoplasmosis to be one of the five neglected parasitic infections. However, a large number of people get infected from toxoplasmosis, but only few patients may experience serious complications. Mostly, the patients suffer from flu-like symptoms until the parasite is controlled by the immune system. The organism can, however, be reactivated in people, including those with compromised immunity. Moreover, active infection may lead to encephalitis (inflammation of the brain), blindness, and mortality. 

The route of transmission of Toxoplasma gondii infection are food, contact with animals (cats), water, soil, and others.

The global toxoplasmosis treatment drugs market is estimated to be valued at US$ 2,859.4 million in 2020 and is expected to exhibit a CAGR of 4.9% during the forecast period (2020-2027).

Figure 1. Global Toxoplasmosis Treatment Drugs Market Value (US$ Mn), by Region, 2020

Toxoplasmosis Treatment Drugs  | Coherent Market Insights

The increasing prevalence of chronic diseases which may lead to toxoplasmosis infection is expected to propel growth of the global toxoplasmosis treatment drugs market

Rising prevalence of cancer and rising chemotherapy procedures may lead to toxoplasmosis infection which is expected to drive the toxoplasmosis treatment drugs market growth. According to Cancer Research U.K., factsheet around 17 million people were diagnosed with cancer in 2018.

According to the same source, the cancer type and new cancer cases in 2018 globally are as follows.

 Rank Cancer Type New Cases Diagnosed in 2018

1

Lung

2,093,876

2

Breast

2,088,849

3

Colorectal

1,800,977

4

Prostate

1,276,106

5

Stomach

1,033,701

Rising number of toxoplasmosis cases is the major factor driving the toxoplasmosis treatment drugs market over the forecast period. According to the World Health Organization estimates - Foodborne Disease Burden Epidemiology Reference Group 2007-2015, the global number of Toxoplasma gondii infection are as follows

  • Foodborne Illnesses: 10,280, 089
  • Foodborne Deaths: 684
  • Foodborne Years Lived with Disability (YLDs): 7,63,326
  • Foodborne Years of Life Lost (YLLs): 62,899
  • Foodborne Disability Adjusted Life Years (DALYs): 8,29,071

However, side effects of drugs such as pyrimethamine used in treatment of Toxoplasmosis include hypersensitivity reactions that can occasionally be severe, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and hyperphenylalaninemina which is expected to hamper the market growth. Moreover, the drugs used in toxoplasmosis treatment may produce megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, neutropenia, atrophic glossitis, hematuria, and disorders of cardiac rhythm.

High price of drugs used in the treatment of toxoplasmosis is the major restraining factor hindering the global toxoplasmosis treatment drugs market over the forecast period. For instance, the price of Daraprim is very high – with the list price for one month supply (60 tablets) was nearly US$ 45,000 in 2018 in the U.S.

CMI table icon

Toxoplasmosis Treatment Drugs Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 2,859.4 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.9% 2027 Value Projection: US$ 3,996.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • Indication: Chronic Toxoplasmosis Infection, Acute Toxoplasmosis Infection.
  • Route of Administration: Parenteral, Oral.
  • Drug Class: Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Folic Acid, Others.
  • Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies.
Companies covered:

Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd., Mangalam Drugs and Organics Ltd., Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and Baxter International Inc.

Growth Drivers:
  • Rising prevalence of Toxoplasmosis Infection
  • Rising cancer cases and chemotherapy procedures
  • Rise in launch of new products
Restraints & Challenges:
  • Side effects of toxoplasmosis treatment drugs 
  • High cost of  toxoplasmosis treatment drugs

Figure 2. Global Toxoplasmosis Treatment Drugs Market Share (%), by Route of Administration, 2020

Toxoplasmosis Treatment Drugs  | Coherent Market Insights

Global Toxoplasmosis Treatment Drugs Market – Regional Analysis.

On the basis of region, the global toxoplasmosis treatment drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to dominate the global toxoplasmosis treatment drugs market during the forecast period, owing to increasing cancer cases in the region and rising number of chemotherapy procedures. For instance, according to the Cancer Treatment & Survivorship Facts & Figures 2019-2021 report published by the American Cancer Society, Inc., the estimated number of cancer cases in the U.S. was around 16,920,370, as of January 1, 2019.

Moreover, according to the same source, the estimated number of cancer prevalence in the U.S. by cancer type are as follows.


Cancer Type

Male

Cancer Type

Female
January 1, 2019 January 1, 2019 January 1, 2030 January 1, 2030
Prostate 3,650,030 5,017,810 Breast 3,861,520 4,957,960
Colon & rectum 776,120 994,210 Uterine corpus 807,860 1,023,290
Melanoma of the skin 684,470 936,980 Colon & rectum 768,650 965,590
Urinary bladder 624,490 832,910 Thyroid 705,050 989,340
Non-Hodgkin lymphoma 400,070 535,870 Non-Hodgkin lymphoma 357,650 480,690
Leukemia 256,790 352,900 Ovary 249,230 297,580

Global Toxoplasmosis Treatment Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic. The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector.

Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global toxoplasmosis treatment drugs market during the forecast period.

Many researchers has started studying to determine the link between COVID-19 and toxoplasmosis. For instance, in May 2020, the scientist from the University of Szczecin, the University of Life Sciences in Pozna? and their colleagues from Hungary, France, and China  studied and determined whether there was any link between COVID-19 cases and toxoplasmosis spread by cats and by the protozoan Toxoplasma gondii. The scientist concluded that the interactions between many pathogens can influence the emergence of various diseases and an analysis of toxoplasmosis and coronavirus data from 86 countries showed that most cases of the parasitic disease coincided with a slower spread of COVID-19.

Key Players

Major players operating in the global toxoplasmosis treatment drugs market are Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd., Mangalam Drugs and Organics Ltd., Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and Baxter International Inc.

Toxoplasma gondii is an intracellular parasite, which can cause lifelong infection. The infection lives in the brain and sometimes in the eyes in about 30 percent of all humans. It is caused due to drinking contaminated water, consuming infected undercooked meat, or exposure to these parasites in soil. These parasites usually occur in unborn babies, newborns, children and adults. While most healthy adults who are exposed to the parasite never experience any serious symptoms, but dormant, unrecognized, smoldering infections can emerge years later in immune-compromised patients.

Market Dynamics

Increasing incidence of cancer is expected to increase the chemotherapy procedures leading to the toxoplasmosis infection, and thereby driving the market growth over the forecast period. According to the World Cancer Research Fund International’s report, in 2018 lung cancer was at first position in the total number of cancer cases worldwide, accounting for 2,093,876 new cases worldwide in 2018. According to the same source, breast cancer accounted second position and the new cases reported was 2,088,849 globally in 2018.

Rising number of chemotherapy procedures can lead to increase in the number of toxoplasmosis infection thereby assisting the market growth. According to the Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, in November 2020, stated that nearly 650,000 cancer patients in the U.S. receive chemotherapy in an outpatient oncology clinic annually.

Increasing prevalence of Acquired Immunodeficiency Syndrome (AIDS) caused due to HIV may lead to low immunity and toxoplasmosis infection and, thereby, drive the growth of toxoplasmosis treatment drugs market during the forecast period. For instance, according to the UNAIDS, 2019, around 1.7 million new cases of HIV infection was registered globally in 2018.

Key features of the study:

  • This report provides in-depth analysis of the global toxoplasmosis treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global toxoplasmosis treatment drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd., Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd, and Baxter International Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global toxoplasmosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global toxoplasmosis treatment drugs market.

Detailed Segmentation:

  • Global Toxoplasmosis Treatment Drugs Market, By Indication:
    • Chronic Toxoplasmosis Infection
    • Acute Toxoplasmosis Infection
  • Global Toxoplasmosis Treatment Drugs Market, By Route of Administration:
    • Parenteral
    • Oral
  • Global Toxoplasmosis Treatment Drugs Market, By Drug Class:
    • Pyrimethamine
    • Spiramycin
    • Leucovorin
    • Sulfadiazine
    • Folic Acid
    • Other
  • Global Toxoplasmosis Treatment Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Toxoplasmosis Treatment Drugs Market, By Region:
    • North America
      • By Indication:
        • Chronic Toxoplasmosis Infection
        • Acute Toxoplasmosis Infection
      • By Route of Administration
        • Parenteral
        • Oral
      • By Drug Class
        • Pyrimethamine
        • Spiramycin
        • Leucovorin
        • Sulfadiazine
        • Folic Acid
        • Other
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Indication:
        • Chronic Toxoplasmosis Infection
        • Acute Toxoplasmosis Infection
      • By Route of Administration
        • Parenteral
        • Oral
      • By Drug Class
        • Pyrimethamine
        • Spiramycin
        • Leucovorin
        • Sulfadiazine
        • Folic Acid
        • Other
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Indication:
        • Chronic Toxoplasmosis Infection
        • Acute Toxoplasmosis Infection
      • By Route of Administration
        • Parenteral
        • Oral
      • By Drug Class
        • Pyrimethamine
        • Spiramycin
        • Leucovorin
        • Sulfadiazine
        • Folic Acid
        • Other
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Indication:
        • Chronic Toxoplasmosis Infection
        • Acute Toxoplasmosis Infection
      • By Route of Administration
        • Parenteral
        • Oral
      • By Drug Class
        • Pyrimethamine
        • Spiramycin
        • Leucovorin
        • Sulfadiazine
        • Folic Acid
        • Other
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Indication:
        • Chronic Toxoplasmosis Infection
        • Acute Toxoplasmosis Infection
      • By Route of Administration
        • Parenteral
        • Oral
      • By Drug Class
        • Pyrimethamine
        • Spiramycin
        • Leucovorin
        • Sulfadiazine
        • Folic Acid
        • Other
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Indication:
        • Chronic Toxoplasmosis Infection
        • Acute Toxoplasmosis Infection
      • By Route of Administration
        • Parenteral
        • Oral
      • By Drug Class
        • Pyrimethamine
        • Spiramycin
        • Leucovorin
        • Sulfadiazine
        • Folic Acid
        • Other
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Vyera Pharmaceuticals LLC*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Taj Accura Pharmaceuticals Ltd
    • Mangalam Drugs and Organics Ltd.
    • Cerovene Healthcare PVT LTD
    • Greenstone LLC
    • Amneal Pharmaceuticals, Inc.
    • Turing Pharmaceuticals
    • Hoffmann-La Roche AG
    • Teva Pharmaceutical Industries Ltd
    • Baxter International Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global toxoplasmosis treatment drugs market size is estimated to be valued at US$ 2,859.4 million in 2020 and is expected to exhibit a CAGR of 4.9% between 2020 and 2027.
The rising number of toxoplasmosis cases, rising number of chronic diseases such as cancer, sexually transmitted diseases, are driving the market growth.
The oral segment is expected to be the leading route of administration segment in the market during the forecast period (2020-2027).
North America toxoplasmosis treatment drugs market is expected to generate highest revenue share during the forecast period.
Major players operating in the market are Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd., Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and Baxter International Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo